CA3204723A1 - Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function - Google Patents

Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function

Info

Publication number
CA3204723A1
CA3204723A1 CA3204723A CA3204723A CA3204723A1 CA 3204723 A1 CA3204723 A1 CA 3204723A1 CA 3204723 A CA3204723 A CA 3204723A CA 3204723 A CA3204723 A CA 3204723A CA 3204723 A1 CA3204723 A1 CA 3204723A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
cdr
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3204723A
Other languages
English (en)
French (fr)
Inventor
Yik Andy Yeung
David Liu
Renee GREER
Henry Nguyen
Sindy Liao CHAN
Sherman Michael CHIN
Paul MESKO
Irene Ni
Ivana DJURETIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asher Biotherapeutics Inc
Original Assignee
Asher Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asher Biotherapeutics Inc filed Critical Asher Biotherapeutics Inc
Publication of CA3204723A1 publication Critical patent/CA3204723A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
CA3204723A 2020-12-09 2021-12-08 Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function Pending CA3204723A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063123387P 2020-12-09 2020-12-09
US63/123,387 2020-12-09
US202163169604P 2021-04-01 2021-04-01
US63/169,604 2021-04-01
PCT/US2021/062485 WO2022125712A1 (en) 2020-12-09 2021-12-08 Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function

Publications (1)

Publication Number Publication Date
CA3204723A1 true CA3204723A1 (en) 2022-06-16

Family

ID=81973973

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3204723A Pending CA3204723A1 (en) 2020-12-09 2021-12-08 Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function

Country Status (8)

Country Link
US (1) US20240010695A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259645A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023552829A (cg-RX-API-DMAC7.html)
KR (1) KR20230129423A (cg-RX-API-DMAC7.html)
AU (1) AU2021396247A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204723A1 (cg-RX-API-DMAC7.html)
TW (1) TW202237630A (cg-RX-API-DMAC7.html)
WO (1) WO2022125712A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230112632A (ko) * 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
CN118206629B (zh) * 2022-12-16 2025-12-02 深圳莱芒生物科技有限公司 一种细胞因子白细胞介素10的突变体及其制备方法和应用
WO2024131600A1 (zh) * 2022-12-24 2024-06-27 广东菲鹏制药股份有限公司 Il10突变体、融合蛋白和药物
WO2026112381A1 (en) * 2024-11-22 2026-05-28 The Regents Of The University Of California Vaccines using macrophage suppression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001231532A1 (en) * 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
WO2004044006A1 (en) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
BR112016016658A2 (pt) * 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
CN111655717A (zh) * 2018-01-26 2020-09-11 豪夫迈·罗氏有限公司 IL-22 Fc融合蛋白及使用方法
JP2022512746A (ja) * 2018-10-19 2022-02-07 アンブルックス,インコーポレイテッド インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
TW202031284A (zh) * 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
CN113811549A (zh) * 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白

Also Published As

Publication number Publication date
WO2022125712A1 (en) 2022-06-16
TW202237630A (zh) 2022-10-01
WO2022125712A9 (en) 2022-07-21
EP4259645A1 (en) 2023-10-18
AU2021396247A1 (en) 2023-07-06
US20240010695A1 (en) 2024-01-11
JP2023552829A (ja) 2023-12-19
EP4259645A4 (en) 2025-03-12
KR20230129423A (ko) 2023-09-08

Similar Documents

Publication Publication Date Title
AU2020287373B2 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
JP7847584B2 (ja) 免疫細胞機能をモジュレートするためのcd8抗原結合分子を有する融合物
JP7662516B2 (ja) Pd-1標的化il-15/il-15rアルファfc融合タンパク質およびその組み合わせ療法での使用
US20240010695A1 (en) Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
KR20160007604A (ko) 이중특이성 작제물 및 다양한 질병의 치료에서의 이의 용도
WO2020172631A2 (en) Untargeted and targeted il-10 fc-fusion proteins
TW202235104A (zh) 雙功能分子
US20250339519A1 (en) Combination of cytokine fusion proteins with cd8 antigen binding molecules
CN116829577A (zh) 用于调节免疫细胞功能的突变型白介素-10多肽与抗原结合分子的融合物
CN116997362A (zh) 含调节免疫细胞功能的cd8抗原结合分子的融合物
EA052306B1 (ru) Слитые белки и их применение, полинуклеотид, кодирующий их, вектор экспрессии, выделенная клетка-хозяин, способ получения слитого белка, фармацевтическая композиция, способ лечения рака, способ размножения т-клеток ex vivo
WO2023221936A9 (zh) 双功能蛋白质及其制剂和用途
HK40093420A (en) Bi-functional molecules

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241112

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241112

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251205

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260203

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205